Beyond Amyloid and Tau: Alzheimer’s Drug Developer Sees Early Clinical Success for Immunotherapy-Based Approach
ImmunoBrain's approach contrasts with decades of conventional thinking among researchers, which held that Alzheimer’s was a disease of toxic proteins—an outgrowth of thinking that immune activity in the brain was in itself a sign of pathology.